As of October 2026, retatrutide is not approved by the Therapeutic Goods Administration (TGA) and is not commercially available in Australia as an approved medicine.

Retatrutide remains an investigational drug undergoing clinical development. The TGA states that it has not been approved in Australia or by a comparable international regulator.  

That does not mean products labelled as retatrutide cannot be found online in Australia. They can. But a product being advertised or sold online is not the same as retatrutide being approved for therapeutic use.

Current status, October 2026: Retatrutide remains investigational. There is no TGA-approved retatrutide medicine commercially available in Australia.

Is Retatrutide Approved by the TGA?

No. Retatrutide has not been approved by the TGA.

Peptide products used for therapeutic purposes are regulated as therapeutic goods in Australia. Products not included in the Australian Register of Therapeutic Goods (ARTG) are generally considered unapproved therapeutic goods.

In its guidance on unapproved peptide products, the TGA specifically identifies retatrutide as an example. These products have not been evaluated by the TGA for safety, quality or effectiveness.  

This distinction matters. Retatrutide has generated substantial clinical interest, but promising trial results do not amount to regulatory approval.

Regulatory approval and clinical safety are also different questions. Our analysis of whether retatrutide is safe examines the Phase 2 and Phase 3 safety evidence and what remains unknown.

Why Can You Find Retatrutide for Sale Online in Australia?

Searching online can make the regulatory position confusing. Products labelled “retatrutide”, “reta”, “R-10” and “R-20” have been promoted and sold despite retatrutide not being an approved medicine in Australia.

Online availability is not the same as TGA approval.

In June 2026, Victoria’s Department of Health reported six cases of acute liver injury associated with an unapproved product labelled Retatrutide. The products were also labelled Reta, R-10 or R-20. The department said the toxic effects were possibly associated with a contaminant.  

Then, in September 2026, the TGA investigated a product sold as retatrutide following a serious adverse event. The consumer experienced uncontrollable vomiting, suffered a torn oesophagus and required hospital treatment.

Laboratory testing found no retatrutide in the product. Instead, the TGA detected undeclared semaglutide at approximately eight times the level found in semaglutide products assessed by the TGA and included in the ARTG.  

This finding needs to be interpreted carefully. It relates to the product tested and does not establish what every product marketed as retatrutide contains.

What it does demonstrate is that a product label alone cannot establish what is actually in the vial.

This distinction is also important for products marketed online as reta peptide. A name on a vial does not establish that it contains the same molecule characterised in published retatrutide research.

Is Online Retatrutide the Same as Clinical-Trial Retatrutide?

It cannot be assumed to be.

Retatrutide used in clinical trials is a defined investigational drug studied under controlled clinical-trial conditions. A product sold online using the same name does not automatically have the same identity, concentration, purity or manufacturing controls.

This also matters when interpreting adverse events. The retatrutide side effects observed in controlled clinical trials relate to the investigational drug studied in those trials. Adverse events involving products of uncertain identity bought online should not automatically be attributed to pharmaceutical retatrutide itself.

The distinction is no longer theoretical in Australia. TGA laboratory testing has already found that at least one product sold as retatrutide contained no retatrutide.  

When Could Retatrutide Become Available in Australia?

There is currently no confirmed date for when retatrutide will become an approved medicine in Australia.

Its clinical development has, however, progressed considerably.

In July 2026, Eli Lilly reported positive results across five Phase 3 studies and said it had the clinical data package to support global regulatory submissions for several potential retatrutide indications. Lilly also said it plans to submit retatrutide for US regulatory approval in the first quarter of 2027.  

Our separate analysis of what retatrutide does examines its mechanism and clinical evidence in more detail.

The clinical evidence has also expanded to include a direct comparison with semaglutide. Our retatrutide vs Ozempic analysis examines the Phase 3 findings, including weight loss, blood sugar control and adverse events.

For Australian availability, successful clinical trials and regulatory approval are separate stages. A simplified pathway is:

Phase 3 evidence → regulatory submission → TGA assessment → ARTG inclusion → Australian commercial availability

At the time of writing, there is no confirmed Australian approval date. Lilly’s plans for US and global regulatory submissions should not be treated as evidence that retatrutide will become available in Australia on a particular date.

Until there is an Australian regulatory submission and subsequent TGA decision, any prediction about an Australian launch date remains speculative.

So, Is Retatrutide Available in Australia?

As of October 2026, retatrutide is not available in Australia as a TGA-approved medicine.

Products labelled as retatrutide can be found online, but that should not be confused with regulatory approval or with the investigational retatrutide used in controlled clinical trials.

Australian regulators have raised concerns about unapproved peptide products, while retatrutide’s clinical development continues to advance. There is currently no confirmed date for TGA approval or commercial availability in Australia.

Retatrutide Australia follows the clinical and regulatory evidence as it develops, with a focus on primary research and Australian regulatory sources.

FAQs

Can you buy retatrutide in Australia?

Retatrutide is not currently available as a TGA-approved medicine in Australia. Products labelled as retatrutide are sold through some online channels, but their availability does not mean they are TGA approved or equivalent to the retatrutide used in clinical trials.

Can you get retatrutide through a clinical trial in Australia?

Retatrutide remains an investigational drug and is being studied through clinical trials. Participation depends on whether a relevant study is recruiting, its eligibility criteria and the locations of participating trial sites. Trial status and recruitment can change, so access should be checked against the relevant official clinical-trial record.

When will retatrutide be available in Australia?

There is currently no confirmed Australian availability date. Lilly has announced plans for a US regulatory submission in the first quarter of 2027 and has said its Phase 3 data package supports global submissions. Australian availability would still depend on the applicable Australian regulatory process and a subsequent TGA decision.

Research Sources

Therapeutic Goods Administration. TGA Tests Counterfeit Retatrutide Product Following Serious Adverse Event Report. September 2026.

Therapeutic Goods Administration. Understanding Your Responsibilities When Importing, Compounding and Supplying Unapproved Peptide Products. April 2026.

Victorian Department of Health. Toxicity Linked to Unapproved Peptide Product Labelled Retatrutide. June 2026.

Eli Lilly and Company. Lilly’s Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials. July 2026.